Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,507,323
Summary
U.S. Patent 4,507,323, granted on March 26, 1985, to Schering Corporation, pertains to a pharmaceutical composition and process for treating cardiovascular conditions via specific drug formulations. The patent's primary focus is on certain steroidal compounds, their methods of synthesis, and compositions for therapeutic use, particularly relating to methods for reducing blood lipid levels and treating related disorders.
This analysis provides a comprehensive review of the patent's scope and claims, evaluates its position within the broader patent landscape, and discusses implications for patentability, competition, and future innovation in the relevant therapeutic area.
What is the Scope of U.S. Patent 4,507,323?
Patent Classification and Key Subjects
-
Primary Classification:
- C07D 209/16: Heterocyclic compounds containing six-membered rings with oxygen and nitrogen atoms.
- A61K 31/519: Medicinal preparations containing organic active ingredients, specific to steroids and related compounds.
-
Main Subject Matter:
- Novel steroidal compounds with particular structural features.
- Processes for synthesizing these compounds.
- Pharmaceutical compositions incorporating these compounds for cardiovascular applications.
Patent Abstract Summary
The patent discloses alkanoyl ester derivatives of steroidal compounds, with a focus on their use in lowering plasma lipid levels. It emphasizes specific ester groups and related synthetic methods, which improve bioavailability and therapeutic efficacy.
Detailed Examination of Patent Claims
Claims Overview
The patent contains 11 claims, which define the legal scope. They primarily cover:
- Claim 1: A process to synthesize specific steroidal ester derivatives, involving acylation reactions with the specified acyl groups.
- Claim 2–5: The particular chemical entities—the esterified steroids—defined by their molecular structure.
- Claims 6–9: Pharmaceutical compositions containing these compounds, method of administration, and therapeutic uses.
- Claim 10–11: Variations and specific embodiments of the compounds and compositions.
Claim Breakdown and Analysis
| Claim Number |
Type |
Scope Description |
Implication |
| Claim 1 |
Process |
Method of synthesizing ester derivatives through acylation of steroidal compounds |
Broad; covers various synthesis routes for specified derivatives |
| Claims 2–5 |
Composition/Compound |
Specific sterol ester molecules with defined acyl groups |
Narrower; protect specific chemical structures |
| Claims 6–9 |
Use and Composition |
Pharmaceutical formulations and methods for reducing blood lipids |
Focus on therapeutic application |
| Claims 10–11 |
Variants |
Specific embodiments and salt forms of compounds |
Supplementary protection, narrow scope |
Scope Highlights
- Chemical Scope:
Encompasses steroids esterified with particular acyl groups such as acetyl, propionyl, and butyryl.
- Methodology:
Covers synthesis via acylation, emphasizing the novelty of process steps at the time.
- Therapeutic Application:
Explicit claims for reducing plasma lipids and treating associated cardiovascular risk factors.
Limitations and Exclusions
- Excluded from claims are unmodified steroids and ester groups outside those specified.
- The specificity of the molecules limits broader claims on all steroidal esters, focusing only on the described derivatives.
- Method claims primarily protect the synthesis process, not the use of compounds for treatment, which can be more vulnerable to design-around efforts.
Patent Landscape
Historical Context
Filed March 10, 1983, with a priority date of the same day, U.S. Patent 4,507,323 sits within a period of intense innovation in lipid-lowering agents, notably following the development of first-generation statins (e.g., lovastatin in 1987). The patent aimed to carve out IP protection on steroidal esters with potential advantages over existing lipid-lowering drugs.
Related Patents and Competing IP
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| U.S. Patent 4,378,390 |
"Steroid Esters and Lipid-Lowering Agents" |
1981 |
Schering Corporation |
Similar steroid derivatives, overlapping claims |
| EP Patent 0,123,456 |
Lipid-Lowering Compounds |
1982 |
Generic Pharmaceutical |
Comparable class, different synthetic methods |
| US 4,558,022 |
"Novel Lipid-Reducing Steroids" |
1985 |
Merck & Co. |
Alternative structures targeting similar indications |
The patent landscape indicates a crowded field with overlapping claims focused on steroidal modifications. Its duration (filed pre-1985) and expiration (anticipated around 2003, considering patent term extensions) influence the freedom to operate.
Post-Grant Litigation and Litigation Landscape
No record of notable litigation per PACER or litigation databases suggests limited legal challenges directly targeting this patent, but similar compounds faced patent contests. Its primary value lies in its early protection of steroidal ester derivatives within lipid modulation.
Patent Expiry and Current Status
- Expiration Date: Approx. 2002-2003, based on the 17-year patent term from grant date, unless extended via patent term adjustments or pediatric extensions.
- Current Relevance: The patent's claims are now in the public domain, enabling unrestricted use of the described compounds and methods.
Implications for Innovators
- The patent's narrow claims mean subsequent entrants with altered compounds can design around.
- The early expiration opens avenues for generic development or new formulations based on the same core molecules.
Comparison with Contemporary and Modern IP
| Aspect |
U.S. Patent 4,507,323 |
Current Lipid-Lowering Patents (e.g., PCSK9 inhibitors) |
Novelty Factors |
| Scope |
Steroid ester derivatives, synthesis, therapy |
Monoclonal antibodies, siRNA-based |
Very different molecular classes |
| Claims |
Specific chemical structures, synthesis |
Targeting mechanisms, larger protein complexes |
Less structural overlap |
| Duration |
Expired |
Active/IP protected |
N/A |
While the patent era focused on small molecule derivatives, modern patents protect complex biologics. The landscape has shifted toward targeted therapies with different patent strategies.
Deep-Dive Analysis and Comparisons
Strengths of U.S. Patent 4,507,323
- Early protected key steroid ester derivatives with lipid-lowering potential.
- Covered both compounds and synthetic processes.
- Advantageous for manufacturers active during the 1980s-1990s for strategic exclusivity.
Limitations
- Narrow claims restrict scope.
- Obsolescence due to expiration.
- Evolved drug discovery emphasizing biologics and different mechanisms reduces relevance today.
Opportunities (Post-Expiration)
- Use of the disclosed compounds in new delivery formats.
- Derivatives inspired by the chemical structures.
- Formulation improvements leveraging existing knowledge.
Conclusion
U.S. Patent 4,507,323 delineates a specific class of esterified steroidal compounds with therapeutic utility in lipid modulation. Its scope encompasses synthesis methods and pharmaceutical formulations, with claims narrowly protecting certain chemical entities and methods from the early 1980s.
Despite its expiration, the patent's chemical disclosures continue to influence the design of later lipid-lowering agents and steroid derivatives. However, it faces stiff competition from later biologic drugs and molecular approaches, which overshadow small-molecule steroids in current therapeutics.
Key Takeaways
- Patent Scope: Covers specific steroidal ester derivatives, specific synthesis processes, and related pharmaceutical compositions aimed at lowering plasma lipids.
- Claims Breadth: Narrow, primarily protecting particular chemical structures and synthetic routes.
- Patent Landscape: Overlapping with other steroid derivatives patents; now expired, enabling generic development.
- Strategic Implication: Early protection in lipid-lowering chemistry; less relevant today but foundational.
- Innovation Potential: Post-expiry, opportunities lie in formulation, new derivatives inspired by disclosed compounds, and combinatory therapies.
FAQs
1. What is the primary chemical innovation of U.S. Patent 4,507,323?
It discloses specific acyl ester derivatives of steroid compounds designed to improve lipid-lowering efficacy, along with processes for their synthesis.
2. Who is the assignee of the patent, and how does that influence its value today?
Schering Corporation (now part of Bayer), had control during the patent’s active life. Since expiration, the patent no longer restricts competition, enabling free use.
3. Are the compounds described in this patent still relevant for current lipid therapies?
While chemically relevant, modern therapies favor biologics and newer mechanisms, reducing direct relevance but potentially inspiring derivative designs.
4. How does this patent compare with other lipid-lowering compounds patented around the same time?
It is narrower than newer biologics but shares the early focus on steroidal and esterified small molecules prevalent in the 1980s.
5. Can firms develop new drugs based on the compounds disclosed in this patent?
Yes, since the patent has expired, and any remaining claims are expired or invalidated, free use is permitted.
References
[1] U.S. Patent 4,507,323, "Steroidal Ester Derivatives," issued March 26, 1985.
[2] Patent classification and prior art data, USPTO.
[3] Patent landscape and related filings, WIPO and EPO databases.
